Developmental outcome in newborn infants treated for acute respiratory failure with extracorporeal membrane oxygenation: present experience

K Khambekar, S Nichani, D K Luyt, G Peek, R K Firmin, D J Field, H C Pandya


Objective: To describe the later health status of newborn infants who received extracorporeal membrane oxygenation (ECMO) for acute respiratory failure in the era after the UK ECMO trial.

Design: Prospective follow up study of newborn infants who received ECMO at a single centre between January 1997 and January 2001.

Setting: Departments of ECMO and Paediatric Intensive Care, University Hospitals of Leicester.

Patients: All babies who received ECMO within 14 days of birth.

Interventions: Neurodevelopment screening using the schedule for growing skills-II (SGS-II) assessment tool.

Main outcome measures: Survival at 12 months of age by disease and functional development at follow up.

Results: A total of 145 neonates received ECMO for treatment of respiratory failure. Of these, 108 (75%) were alive at 1 year of age. There were no deaths in children treated for respiratory failure secondary to meconium aspiration syndrome (73/145). Ninety three (86% of survivors) infants attended a follow up visit at 11–19 months postnatal age. Eighty two were classed as normal, seven as having “impairment”, and four as having “severe disability”.

Conclusions: Most newborn infants with acute respiratory failure treated with ECMO will have a normal neurodevelopment screening assessment at 11–19 months of postnatal age. There is no evidence to suggest that changes in neonatal practice since the UK ECMO trial have led to changes in outcome of infants undergoing ECMO therapy.

METHODS

Case identification
The names of all babies who received ECMO aged less than 14 days at Glenfield Hospital between January 1997 and January 2001 were obtained from an in house database.

Patient details (basic characteristics, diagnosis, treatments before ECMO, and outcome after ECMO) were retrieved from the case records.

Developmental assessment
Neurodevelopment was determined at 11–19 months of age using the schedule for growing skills-II (SGS-II), a widely used screening tool which assesses development in 10 “skill” domains (active and passive posture, locomotor, manipulative, vision, speech and hearing language, interactive and self care social, cognitive). SGS-II is based on the Sheridan developmental sequences and has been validated against Griffiths mental developmental scales. Its forerunner was used in the UK national child encephalopathy study. All children were examined by either KK or HP, and in five cases by both, to ensure that the tool was used in a consistent manner.

Data analysis
Individual skill domain and overall developmental quotients (DQs) for each child were calculated by dividing “achieved” individual and overall scores by mean scores for the child’s age range (10–11, 12–14, 15–17, and 18–23 months). Children who were blind or deaf and/or had an overall DQ score <50% predicted were concluded to have “severe disability”.

Abbreviations:
CDH, congenital diaphragmatic hernia; DQ, developmental quotient; ECMO, extracorporeal membrane oxygenation; HFOV, high frequency oscillatory ventilation; iNO, inhaled nitric oxide; MAS, meconium aspiration syndrome; OI, oxygenation index; PPHN, persistent pulmonary hypertension of the newborn; SGS-II, schedule for growing skills-II
disability”, whereas children with overall DQ scores of 50–69% predicted, or a locomotor DQ of less than 70% predicted, or were receiving regular anticonvulsants, or needed tube feeding, or required oxygen were concluded to have “impairment”. Children with an overall DQ greater than 70% predicted were classed as “normal”. Comparisons of the present data with UK ECMO trial data were made using a $\chi^2$ test for dichotomous data. $p<0.05$ was considered significant.

RESULTS
Between January 1997 and January 2001, 152 newborn infants aged less than 14 days received ECMO therapy in our unit (fig 1). Seven infants with heart lesions were excluded. Between January 1997 and January 2001, 152 newborn infants aged less than 14 days received ECMO therapy in our unit (fig 1). Seven infants with heart lesions were excluded. Between January 1997 and January 2001 at Glenfield Hospital between 1997 and 2001 inclusive at Glenfield Hospital, Leicester. PICU, Paediatric intensive care unit.

Twelve month survival for the cohort was 75%. Although no deaths were recorded in infants with MAS, 36 infants died in hospital and one child with congenital diaphragmatic hernia (CDH) died after discharge. A third of non-survivors had CDH. Six other babies had untreatable respiratory conditions. Figure 1 and table 2 give the details.

Table 3 and 4 and fig 2 give the health status of the 93/108 children assessed. The mean overall DQ score for the group was 105. Mean group scores for individual skill domains varied between 92 (cognitive) and 119 (locomotor). Data for active and passive posture domains are not shown, as nearly all children received maximum scores in these skills. Eighty two children were classed as normal, seven as having impairment, and four as having severe disability. No infant was blind, totally deaf, or receiving oxygen therapy. All four children with severe disability had overall and locomotor DQ scores of less than 50 and additional health problems such as squint and tube feeding. One had trisomy 21. Four of seven children with impairment had DQ scores <70 in the locomotor skill domain. One of them also required a hearing aid. The three other children with impairment were receiving supplemental feeding. Figure 2 is a scatter plot showing individual locomotor skill domain DQ scores. Four children with DQ scores in the normal range had squints. Although the status of the 15 infants who did not receive follow up is uncertain, contact with families and correspondence from referring units suggest that none of these children have severe health problems.

Table 2 Outcome of the 152 infants less than 14 days of age who received extracorporeal membrane oxygenation (ECMO) at Glenfield Hospital between 1997 and 2001

<table>
<thead>
<tr>
<th>Diagnostic category</th>
<th>Survivors (n = 110)</th>
<th>Non-survivors (n = 42)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Congenital heart disease</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>Respiratory disease</td>
<td>108</td>
<td>37</td>
</tr>
<tr>
<td>Sepsis (group B streptococcus)</td>
<td>9 (5)</td>
<td>9 (7)</td>
</tr>
<tr>
<td>Congenital diaphragmatic hernia</td>
<td>3</td>
<td>12</td>
</tr>
<tr>
<td>Alveolar capillary dysplasia</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>Surfactant protein B deficiency</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Declined/lost to follow up</td>
<td>8</td>
<td>0</td>
</tr>
<tr>
<td>Meconium aspiration</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Idiopathic PPHN</td>
<td>4 (2)</td>
<td>0</td>
</tr>
</tbody>
</table>

Values in parentheses are percentages.
PPHN, Persistent pulmonary hypertension of the newborn.

Table 1 Clinical status and treatments before extracorporeal membrane oxygenation (ECMO) in the Glenfield and UK ECMO trial cohorts

<table>
<thead>
<tr>
<th>Age of ECMO</th>
<th>Oxygenation index</th>
<th>Therapies before ECMO</th>
<th>Glenfield (n = 145)</th>
<th>UK ECMO trial (n = 63)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 24 h</td>
<td>&lt; 40</td>
<td>Pulmonary vasodilators excluding iNO</td>
<td>42 (29)</td>
<td>65 (45)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td></td>
<td>&gt; 40</td>
<td>iNO</td>
<td>103 (71)</td>
<td>5 (8)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inotrope</td>
<td>51</td>
<td>110 (75)</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HFOV</td>
<td>65 (39)</td>
<td>50 (79)</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Muscle relaxant</td>
<td>44 (31)</td>
<td>4 (6)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Surfactant</td>
<td>31 (21)</td>
<td>17 (26)</td>
<td>NS</td>
</tr>
<tr>
<td>&gt; 48 h</td>
<td>&lt; 24 h</td>
<td>iNO</td>
<td>70 (48)</td>
<td>23 (37)</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inotrope</td>
<td>44 (31)</td>
<td>23 (37)</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HFOV</td>
<td>31 (21)</td>
<td>17 (26)</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Muscle relaxant</td>
<td>116 (80)</td>
<td>16 (25)</td>
<td>&lt;0.01</td>
</tr>
</tbody>
</table>

Values in parentheses are percentages.
iNO, Inhaled nitric oxide; HFOV, high frequency oscillatory ventilation.
DISCUSSION

The main findings of this report are that survival for newborn infants with severe acute respiratory failure treated with ECMO is excellent and that most survivors are normal on developmental screening at 11–19 months. However, data from other follow up programmes, including that for the UK collaborative ECMO trial, indicate that a full picture regarding the health status of these children will not emerge until later.4

Survival (75%) to 1 year of age for newborns receiving ECMO in the study period is in line with other ECMO programmes and better than reported by the UK collaborative ECMO trial group.1–3 10–12 Infants who died could be divided into a group with congenitally abnormal lungs and a group with normal lungs at birth. Idiopathic persistent pulmonary hypertension of the newborn (PPHN) and sepsis were the only two diagnostic categories in the latter. The group with congenitally abnormal lungs included infants with CDH, alveolar capillary dysplasia, and hereditary surfactant protein B deficiency. All infants with CDH were referred for ECMO therapy before surgical repair. Only a few could be weaned from ECMO support on to mechanical ventilators despite early surgical repair of the hernia and a prolonged (>2 weeks) ECMO run. The disappointing survival for infants with CDH (3/15) is indicative of the severe lung dysplasia present in some children with this disorder, and it is our view that outcome for this subgroup of infants with CDH is unlikely to improve in the absence of an effective “lung growth” strategy, with or without ECMO.

Survival for infants with MAS was 100%, a finding that has been reported by other ECMO programmes.10–12 These observations show that ECMO is a very effective treatment for MAS. Moreover, the data show that zero or near zero mortality is an achievable goal for this disorder. One reason for the excellent survival statistics for MAS may be a general improvement in the care of infants with hypoaxemic respiratory failure. For example, compared with the UK ECMO trial, present day infants were referred earlier in the course of their illness and were more likely to have received treatments known to improve oxygenation, such as surfactant, iNO, and HFOV. It is therefore possible that these treatments, in conjunction with early institution of ECMO, resulted in present day infants having less prolonged and/or profound episodes of hypoaxemia-ischaemia than infants in the UK ECMO trial. The net result is the excellent survival figures for MAS. It is noteworthy that, despite the greater use of surfactant, iNO, and HFOV before ECMO, there was no significant difference in the time of referral for ECMO. This is also encouraging as there had been concern that a strategy of ECMO avoidance, where possible, might result in late referral of a number of infants. The only evidence of such an effect is the 21% of babies whose referral still occurs after 48 hours.

Comparison of the current outcome data with UK ECMO trial data shows more children in the severely disabled category in the present day cohort (even after accounting for the child with trisomy 21 who would have been excluded from the UK ECMO trial), but fewer children with impairment. There are several possible explanations for these differences. Firstly, the better survival rate for the present day cohort compared with the UK ECMO trial equates to about 10 more infants being alive at follow up. These “extra” survivors may have been those most likely to have disability. Although it could be argued that compared with the UK ECMO trial, infants in the present era were less sick (lower OIs) and had a shorter period of postnatal hypoaxemia-ischaemia (earlier referral), neither the time to ECMO referral nor a lower OI correlate with better outcomes.1–4 Differences in assessment methodology may also explain the disparity in developmental outcomes. More specifically, as SGS-II is a screening tool designed to detect definite “normality” and definite “abnormality”, it has little sensitivity for detecting subtle abnormalities. Thus DQ scores above 100 do not indicate above average development, and few children are likely to have DQ scores in the “impairment” range. A third possible explanation is that the missing data on 15 infants have distorted the pattern of results. Finally, the age of assessment may also have distorted the findings, as the UK ECMO trial data show that it is important that follow up continues at least until school age.
SUMMARY AND CONCLUSIONS

In the current era, we have found that most term and near term newborn infants with hypoxaemic respiratory failure treated with ECMO have normal neurodevelopment. The zero mortality for MAS indicates that “normal physical and neurodevelopmental outcome” is a realistic aim for all neonates with severe respiratory failure, but survivors are at high risk of adverse neurodevelopment. These criteria may require modification as more outcome data for specific treatments become available. Hence, as recommended by the American Academy of Paediatrics, we would encourage the collection and publication of data on short and long term outcomes for infants with severe acute respiratory failure on a centre and treatment specific basis. We acknowledge the care provided by all the staff of the Paediatric Intensive Care Unit, Glenfield Hospital, Leicester to babies referred to the ECMO service.

What is already known on this topic

- ECMO is highly effective at improving survival in neonates with severe respiratory failure, but survivors are at high risk of adverse neurodevelopment
- Alternative means of respiratory support are available for use before ECMO, potentially altering the pattern of ECMO referrals and results

What this study adds

- New treatments are being used before referral; there is no evidence that this is delaying the time that otherwise eligible infants will receive ECMO therapy
- There is no evidence of an adverse impact on neurodevelopmental outcome during the second year of life

REFERENCES

Neonate with staphylococcal scalded skin syndrome

This boy was born after an uncomplicated pregnancy and delivery. On the 5th day of life, a small blister was seen on the right buttock and thigh. During the course of a few hours, erythema developed on the trunk and blisters in the napkin area. The patient was admitted to our burn centre, and the diagnosis of staphylococcal scalded skin syndrome (SSSS) was made. His vital functions and temperature remained normal. The skin was reddened and painful, with 50% of the total body area covered by blisters. The Nikolsky sign (separation of the superficial skin from the deeper layers on application of light pressure) was positive. The mucous membranes of the mouth and anus were unaffected. During the next few hours the blisters became more extensive, until they involved 90% of the total body area (fig 1).

Skin cultures showed a growth of Staphylococcus aureus, which produces exfoliative endotoxin B. Treatment included administration of intravenous antibiotics and fluid. The fluid amount was adapted to compensate for evaporation through the large wound surface. Normal body temperature was maintained with extra heat in an incubator, and pain was relieved with intravenous morphine and rectal acetaminophen. The wound areas were covered with a polyurethane film (Omniderm). This semipermeable wound cover reduces water permeability and thereby fluid loss. It also creates a favourable environment for epithelisation.

On the third day after admission, epithelisation began and was complete on the 5th day. The patient was discharged home with intact skin, without scars, seven days after admission (fig 2).

M G A Baartmans
M H Maas
J Dokter
Medisch Centrum Rijnmond-Zuid, Rotterdam, the Netherlands

Correspondence to: Dr Baartmans, Medisch Centrum Rijnmond-Zuid, Department of Pediatrics, Postbus 9191, Rotterdam 3007AC, the Netherlands; Baartmansm@mcrz.nl; mgabaartmans@kabelfoon.nl

Competing interests: none declared

REFERENCES

Developmental outcome in newborn infants treated for acute respiratory failure with extracorporeal membrane oxygenation: present experience

K Kambekar, S Nichani, D K Luyt, G Peek, R K Firmin, D J Field and H C Pandya

Arch Dis Child Fetal Neonatal Ed 2006 91: F21-F25 originally published online September 13, 2005
doi: 10.1136/adc.2004.066290

Updated information and services can be found at:
http://fn.bmj.com/content/91/1/F21

These include:

References
This article cites 10 articles, 2 of which you can access for free at:
http://fn.bmj.com/content/91/1/F21#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Child health (1515)
Infant health (857)
Neonatal and paediatric intensive care (341)
Neonatal health (928)
Screening (epidemiology) (234)
Screening (public health) (234)
Paediatric intensive care (7)
Pregnancy (1521)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/